Skin Disorders News

Sixteen patients at a private dermatology practice in Denmark developed delayed-onset urticaria after receiving COVID-19 vaccine boosters between February and June 2022, according to a letter published in Clinical and Translational Allergy.

Patients with atopic dermatitis and moderate to severe ocular surface disease who were treated with dupilumab had higher levels of the biologic in their tears than those with mild or no ocular surface disease, according to study results.

Treatment with ruxolitinib cream was well tolerated and effective with no effect on blood counts or bone growth among children with atopic dermatitis, according to a study published in Annals of Allergy, Asthma & Immunology.

Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily in the first 16 weeks, according to a study published in Clinical and Translational Allergy.

The FDA has approved a supplemental new drug application to expand the use of abrocitinib for adolescents with atopic dermatitis when other systemic drug products are not adequate or advisable, according to a press release.

Change is far from incremental in allergy and asthma care based on the speakers and presentations scheduled for the American Academy of Allergy, Asthma & Immunology Annual Meeting in San Antonio from Feb. 24 to 27.

The prevalence of current eczema increased by 0.98% per decade among adolescents and 1.21% per decade among children over a span of 27 years, according to a study published in Clinical & Experimental Allergy.

Increases in concentrations of grass pollen were associated with increases in risk for food skin prick test reactivity and eczema flares in children, according to a study published in Pediatric Allergy and Immunology.

The FDA has approved a supplemental biologics license application to expand the use of lanadelumab-flyo for prophylaxis of hereditary angioedema attacks in children aged 2 to younger than 12 years, according to a press release.

Children with atopic dermatitis who received dupilumab experienced improvements in disease severity and decreases in severity-associated serum biomarkers, according to a study published in Pediatric Allergy and Immunology.